Virax Biolabs Shakes Hands with Europa Biosite: A Match Made in Biotech Heaven?
Well, well, well! Hold onto your lab coats, folks! We’ve got news hotter than a pipette full of boiling water, as Virax Biolabs Group Limited has decided to play nice with the good folks over at Europa Biosite. As of October 23, 2024, this dynamic duo has inked a distribution agreement that promises to roll out Virax’s ImmuneSelect Research Use portfolio across the United Kingdom and Ireland. That’s right, folks, we are one step closer to solving the mysteries of immune responses and viral diseases – or at the very least, making sure our researchers have some shiny new toys to play with!
ImmuneSelect: Your New Best Friend in Immunology
Now, you might be asking, what on Earth is ImmuneSelect? Well, brace yourselves. This portfolio is like the Swiss Army knife for researchers looking to get into the nitty-gritty of adaptive immunity. Think of it as the clinically-sound equivalent of Pokémon – gotta catch ’em all, but instead of cute creatures, we’re talking about a suite of profiling solutions designed to assess the role of T cell response and immune status. It’s like the researchers are the real-life Ash Ketchums, but for science!
James Foster, CEO of Virax Biolabs, couldn’t contain his excitement. He proclaimed, “We believe this partnership will meaningfully expand our commercial footprint…” which translates roughly to “We’re about to sell a lot more stuff!” And who doesn’t love a good commercial footprint? It’s like a footprint in the sand but with fewer seagulls and more science!
Europa Biosite: The Distribution Wizards
But wait, there’s more! On the other side of the table, we have Martijn Blommaart, Director of Supplier Development at Europa Biosite, assuring us he’s ready to leverage their commercial infrastructure. That’s just fancy-speak for “We’re going to get these products from the lab to the market faster than you can say ‘T cell assay’!” With local technical support thrown into the mix, it seems like ImmuneSelect will soon have no trouble finding its way into laboratories across the UK and Ireland. Talk about customer service!
What’s Inside the ImmuneSelect Toolbox?
Without getting too technical – unless you want to grab a cup of coffee and settle in – the ImmuneSelect offerings include peptide pools targeting everything from SARS-CoV-2 to Lyme Disease, among others. Who knew that battling viruses could be so… trendy? These products are perfect for researchers eager to conduct studies but who might need a bit of help prodding those T cells into action. It’s a veritable buffet of immunological goodies!
To Sum It All Up…
As Virax Biolabs and Europa Biosite gear up for this bold new adventure in biotech, the rest of us can only watch in awe. With Virax’s cutting-edge technology in adaptive immunity and Europa’s distribution prowess, we could be looking at a major leap in our understanding of viral diseases and immune responses. If you’re a researcher in the UK or Ireland, it’s time to get excited. Unless, of course, you’re an actual virus, in which case – run!
For those thirsty for deeper knowledge or just a curious mind wanting to know more, visit Virax Biolabs and Europa Biosite. Who knows? You just might find the secret to your next big breakthrough!
And remember, in the world of science, while there may be mysteries yet to solve, at least we know one thing for sure: Biotech partnerships are the new black!
LONDON, Oct. 23, 2024 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company’s ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience.
“ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe,” said James Foster, CEO of Virax Biolabs. “We believe this partnership will meaningfully expand our commercial footprint in the UK and Ireland and make ImmuneSelect accessible to researchers and pharmaceutical companies as they work to better understand the role of T cell response and immune status.”
“We are happy to partner with innovative companies like Virax Biolabs,” commented Martijn Blommaart, Director of Supplier Development at Europa Biosite. “We look forward to leveraging our commercial infrastructure to quickly deliver and provide local technical support to ensure that ImmuneSelect is available in the UK & Ireland”
About ImmuneSelect
ImmuneSelect is the Company’s portfolio of research products dedicated to investigating adaptive immunity. Products within the ImmuneSelect brand are for research and investigational use only and are not intended to be used as a diagnostics tool. The ImmuneSelect portfolio includes peptide pools covering epitopes from pathogens, optimized for the stimulation of T cells. The initial offerings include pools for SARS-CoV-2, SARS-CoV-2 MHC-1 (“CD8”), Lyme Disease, Cytomegalovirus (“CMV”), Respiratory Syncytial Virus (“RSV”) and Epstein-Barr Virus (“EBV”), which continue to be regularly expanded. ImmuneSelect’s Recombinant Antibodies target cytokines and biomarkers, and they are available in different versions unconjugated to be tested on a range of applications including Flow Cytometry, ELISA and ELISpot/Fluorospot. ImmuneSelect is affordable, easy to use, and is compatible with most standard laboratory equipment.
About Europa Biosite
Europa Biosite is a European supplier of life science products and services, composed of six leading distribution companies: Biomol in Germany, Cambridge Bioscience in the UK and Ireland, LubioScience in Switzerland, Nordic Biosite in the Nordics and Baltics, Sanbio in Benelux and Szabo-Scandic in Austria. The group has a portfolio of over 5 million products, representation in 16 European countries and a highly skilled team of over 150 employees. Europa Biosite is the optimal gateway into the European life science market, maximising sales growth through locally tailored solutions and close supply partnerships.
For more information, please visit https://www.europabiosite.com/.
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
New York, NY 10001
M: 303-482-6405
[email protected]
View original content to download multimedia:
SOURCE Virax Biolabs
